Compare · CNSY vs SYK
CNSY vs SYK
Side-by-side comparison of Cerenome Inc. (CNSY) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNSY and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $118.01B, about 19094.3x CNSY ($6.2M).
- CNSY has been more active in the news (10 items in the past 4 weeks vs 6 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 0 for CNSY).
- Company
- Cerenome Inc.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $6.2M
- $118.01B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 6
- Recent ratings
- 0
- 25
Cerenome Inc.
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest CNSY
- Cerenome Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
- Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
- SEC Form 10-Q filed by Cerenome Inc.
- Cerenome Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
- Chief Business Officer Andrews Ronald Asbury was granted 92,858 stock options (SEC Form 4)
- Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
- Cerenome Appoints Director Ron Andrews as Chief Business Officer
- Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Latest SYK
- Director Ronda E Stryker exercised 3,605 shares at a strike of $122.51, increasing direct ownership by 473% to 4,367 units (SEC Form 4)
- Director Stryker Ronda E sold $178,924,731 worth of shares (550,000 units at $325.32) (SEC Form 4)
- Stryker Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Stryker announces intention to nominate Jim Davis to board of directors
- What 3.4% GDP Growth and a 4.2% Jobless Rate Say About a Hard Day on Wall Street
- SEC Form S-3ASR filed by Stryker Corporation
- SEC Form IRANNOTICE filed by Stryker Corporation
- SEC Form 10-Q filed by Stryker Corporation
- Stryker downgraded by Canaccord Genuity with a new price target
- SEC Form 8-K filed by Stryker Corporation